Trial Profile
Efficacy and safety of the multitarget inhibitor agent su11248 in patients with locally advanced or metastatic hepatocellular carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 25 May 2011
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 25 May 2011 New trial record